Details of the Drug

General Information of Drug (ID: DMSIVND)

Drug Name

Hydroxychloroquine

Synonyms

Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258

Indication

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[1], [2]

Therapeutic Class

Antimalarials

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

335.9

Topological Polar Surface Area (xlogp)

3.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 74% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [5]
Elimination: 27% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 850 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 29.7725 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.57% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 700 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 200 mg/mL [3]

Chemical Identifiers

Formula: C18H26ClN3O
IUPAC Name: 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
Canonical SMILES: CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
InChI: InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
InChIKey: XXSMGPRMXLTPCZ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3652
ChEBI ID: CHEBI:5801
CAS Number: 118-42-3
DrugBank ID: DB01611
TTD ID: D0OJ4L
VARIDT ID: DR00449
INTEDE ID: DR0837
ACDINA ID: D00316

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 7 (TLR7)	TTRJ1K4	TLR7_HUMAN	Antagonist	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Malaria

ICD Disease Classification

1F40-1F45

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Toll-like receptor 7 (TLR7)	DTT	TLR7	3.32E-25	0.44	0.88
Breast cancer resistance protein (ABCG2)	DTP	BCRP	5.18E-17	3.16E-01	7.14E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.29E-36	-3.75E-01	-1.06E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Hydroxychloroquine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Lumefantrine.	Malaria [1F40-1F45]	[38]
-----------

Coadministration of a Drug Treating the Disease Different from Hydroxychloroquine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[39]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Midostaurin.	Acute myeloid leukaemia [2A60]	[40]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Arn-509.	Acute myeloid leukaemia [2A60]	[41]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[40]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Oliceridine.	Acute pain [MG31]	[40]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Ivabradine.	Angina pectoris [BA40]	[41]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Dronedarone.	Angina pectoris [BA40]	[42]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[40]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Levalbuterol.	Asthma [CA23]	[43]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Hydroxychloroquine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[38]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Retigabine.	Behcet disease [4A62]	[40]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Eribulin.	Breast cancer [2C60-2C6Y]	[40]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Hydroxychloroquine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[38]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Bosutinib.	Breast cancer [2C60-2C6Y]	[40]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[40]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[44]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[43]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Pasireotide.	Cushing syndrome [5A70]	[40]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Osilodrostat.	Cushing syndrome [5A70]	[40]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Hydroxychloroquine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[38]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Hydroxychloroquine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[38]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[40]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Deutetrabenazine.	Dystonic disorder [8A02]	[40]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Ingrezza.	Dystonic disorder [8A02]	[40]
Methsuximide	DM6L5VO	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[38]
Stiripentol	DMMSDOY	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Stiripentol.	Epilepsy/seizure [8A61-8A6Z]	[38]
Brivaracetam	DMSEPK8	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Brivaracetam.	Epilepsy/seizure [8A61-8A6Z]	[38]
Lacosamide	DMVM6QR	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Lacosamide.	Epilepsy/seizure [8A61-8A6Z]	[38]
Rufinamide	DMWE60C	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[38]
Eslicarbazepine	DMZREFQ	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[38]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Hydroxychloroquine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[38]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Hydroxychloroquine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[38]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Hydroxychloroquine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[45]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Hydroxychloroquine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Hydroxychloroquine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[42]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[42]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Crizotinib.	Lung cancer [2C25]	[40]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Ceritinib.	Lung cancer [2C25]	[40]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Osimertinib.	Lung cancer [2C25]	[40]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Selpercatinib.	Lung cancer [2C25]	[40]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Hydroxychloroquine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[38]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Vemurafenib.	Melanoma [2C30]	[42]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and LGX818.	Melanoma [2C30]	[40]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Hydroxychloroquine due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[42]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Panobinostat.	Multiple myeloma [2A83]	[46]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Siponimod.	Multiple sclerosis [8A40]	[38]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Fingolimod.	Multiple sclerosis [8A40]	[42]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Ozanimod.	Multiple sclerosis [8A40]	[47]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Romidepsin.	Mycosis fungoides [2B01]	[40]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Hydroxychloroquine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[38]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[42]
E-2007	DMJDYNQ	Moderate	Antagonize the effect of Hydroxychloroquine when combined with E-2007.	Neuropathy [8C0Z]	[38]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Entrectinib.	Non-small cell lung cancer [2C25]	[40]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Lofexidine.	Opioid use disorder [6C43]	[40]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Triclabendazole.	Parasitic worm infestation [1F90]	[40]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Pimavanserin.	Parkinsonism [8A00]	[40]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[48]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Lefamulin.	Pneumonia [CA40]	[49]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Hydroxychloroquine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[38]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Degarelix.	Prostate cancer [2C82]	[41]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and ABIRATERONE.	Prostate cancer [2C82]	[41]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Enzalutamide.	Prostate cancer [2C82]	[41]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Relugolix.	Prostate cancer [2C82]	[41]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Iloperidone.	Schizophrenia [6A20]	[40]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Amisulpride.	Schizophrenia [6A20]	[40]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Asenapine.	Schizophrenia [6A20]	[40]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Hydroxychloroquine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[38]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[40]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[42]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[41]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Pitolisant.	Somnolence [MG42]	[40]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[40]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Lenvatinib.	Thyroid cancer [2D10]	[40]
-----------


⏷ Show the Full List of 75 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Hydroxychloroquine 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7198).
2	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
8	MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
9	Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018 Jun;365(3):447-459.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
20	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
21	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
22	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
23	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
24	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
25	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
26	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
27	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
28	Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
29	Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
30	Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
31	Company report (Iderapharma)
32	TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
33	The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
34	Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
35	Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
36	Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
37	The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9.
38	Cerner Multum, Inc. "Australian Product Information.".
39	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
40	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
41	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
42	Canadian Pharmacists Association.
43	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
44	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
45	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
46	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
47	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
48	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
49	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.